Pulse Biosciences Statistics
Want to see PLSE full AI Analyst Report?
Pulse Biosciences (PLSE) Stock Statistics & Valuation Metrics
Total Valuation
Pulse Biosciences has a market cap or net worth of $3.92B. The enterprise value is $3.41B.
- Market Cap
- $3.92B
- Enterprise Value
- $3.41B
Share Statistics
Pulse Biosciences has 73,548,930 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 73,548,930
- Owned by Insiders
- 68.72%
- Owned by Institutions
- 6.96%
Financial Efficiency
Pulse Biosciences’s return on equity (ROE) is -0.90 and return on invested capital (ROIC) is -85.72%.
- Return on Equity (ROE)
- -0.90
- Return on Assets (ROA)
- -0.76
- Return on Invested Capital (ROIC)
- -85.72%
- Return on Capital Employed (ROCE)
- -0.87
- Revenue Per Employee
- 3,017.241
- Profits Per Employee
- -627.42K
- Employee Count
- 116
- Asset Turnover
- 0.00
- Inventory Turnover
- 11.84
Valuation Ratios
The current PE Ratio of Pulse Biosciences is -45.93. Pulse Biosciences’s PEG ratio is 8.99.
- PE Ratio
- -45.93
- PS Ratio
- 2682.30
- PB Ratio
- 21.60
- Price to FCF
- -62.91
- Price to Operating Cash Flow
- -62.60
- PEG Ratio
- 8.99
Income Statement
In the last 12 months, Pulse Biosciences had revenue of 350.00K and earned -72.78M in profits. Earnings per share was -1.08.
- Revenue
- 350.00K
- Gross Profit
- -1.26M
- Operating Income
- -76.94M
- Pretax Income
- -72.78M
- Net Income
- -72.78M
- EBITDA
- -71.71M
- Earnings Per Share (EPS)
- -1.08
Cash Flow
In the last 12 months, operating cash flow was -63.33M and capital expenditures -370,000, giving a free cash flow of -63.70M billion.
- Operating Cash Flow
- -63.33M
- Free Cash Flow
- -63.70M
- Free Cash Flow per Share
- -0.89
Dividends & Yields
Pulse Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.67%
- Earnings Yield
- -2.22%
Stock Price Statistics
- Beta
- 1.09
- 52-Week Price Change
- 238.78%
- 50-Day Moving Average
- 51.66
- 200-Day Moving Average
- 32.69
- Relative Strength Index (RSI)
- 53.24
- Average Volume (3m)
- 506.63K
Important Dates
Pulse Biosciences upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Pulse Biosciences as a current ratio of 10.53, with Debt / Equity ratio of 9.34%
- Current Ratio
- 10.53
- Quick Ratio
- 10.51
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.02
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Pulse Biosciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Pulse Biosciences EV to EBITDA ratio is -45.39, with an EV/FCF ratio of -59.32.
- EV to Sales
- 2529.52
- EV to EBITDA
- -45.39
- EV to Free Cash Flow
- -59.32
- EV to Operating Cash Flow
- -59.67
Balance Sheet
Pulse Biosciences has $189.19M in cash and marketable securities with $6.36M in debt, giving a net cash position of $182.83M billion.
- Cash & Marketable Securities
- $189.19M
- Total Debt
- $6.36M
- Net Cash
- $182.83M
- Net Cash Per Share
- $2.49
- Tangible Book Value Per Share
- $2.51
Margins
Gross margin is 9.44%, with operating margin of -5821.08%, and net profit margin of -5603.88%.
- Gross Margin
- 9.44%
- Operating Margin
- -5821.08%
- Pretax Margin
- -5603.88%
- Net Profit Margin
- -5603.88%
- EBITDA Margin
- -5573.09%
- EBIT Margin
- -5641.97%
Analyst Forecast
The average price target for Pulse Biosciences is $66.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $66.67
- Price Target Upside
- 25.10% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- 1637.21%
- EPS Growth Forecast
- -6.34%
Scores
- Smart Score
- 10
- AI Score
- 60
